https://www.selleckchem.com/pr....oducts/crenolanib-cp
0001). After matching, 30 patients were allocated to each group and the ages were comparable (78.58 vs. 77.48years, P=0.1738). High-grade perioperative complication rates did not differ between groups both before and after matching. Cancer-specific survival, overall survival and metastasis-free survival were significantly longer in the complete-lymphadenectomy group both before and after matching (all, P0.05). This study suggests that complete-lymphadenectomy may provide therapeutic benefits for older patients. The deci
Curtir
Comentario
Compartilhar
